WH2E:XETRA:XETRA-Invesco S&P World Health Care ESG UCITS ETF Acc EUR (EUR)

ETF | Others |

Last Closing

USD 5.451

Change

0.00 (0.00)%

Market Cap

USD 0.06B

Volume

2.37K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-26 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

+1.20 (+2.33%)

USD 446.30B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

+0.39 (+2.31%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.72 (+2.67%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

+0.64 (+2.29%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.53 (+2.15%)

USD 157.79B
8R80:XETRA Amundi Index Solutions - Amund..

+2.46 (+1.75%)

USD 102.09B
JARI:XETRA Amundi Index Solutions - Amund..

+0.57 (+1.26%)

USD 101.20B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

+1.22 (+2.39%)

USD 85.64B
EUNL:XETRA iShares Core MSCI World UCITS ..

+0.56 (+0.54%)

USD 84.07B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+2.28 (+0.38%)

USD 80.38B

ETFs Containing WH2E:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.71% 47% F 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.71% 45% F 49% F
Trailing 12 Months  
Capital Gain 7.96% 47% F 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.96% 45% F 49% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 5.53% 48% F 49% F
Dividend Return 5.53% 47% F 47% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.26% 69% C- 76% C+
Risk Adjusted Return 66.90% 61% D- 65% D
Market Capitalization 0.06B 23% F 21% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.